Structure via PubChem · Public domain (PubChem)
روفینامید
Sign in to saveAlso known as RUF331, Banzel®, CGP-33101, Inovelon®, RUF-331, Xilep, Rufinamide
Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.
Chemical data
- Formula
- C10H8F2N4O
- Molecular weight
- 238.19 g/mol
- IUPAC name
- 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide
- SMILES
- C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F
- InChIKey
- POGQSBRIGCQNEG-UHFFFAOYSA-N
- XLogP
- 0.7
- Polar surface area
- 73.8 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2007
- Admin. routes
- oral
- Indications
- Seizure, epilepsy, pain, Lennox-Gastaut syndrome
via ChEMBL · EBI
Research
393 papers- Rufinamide.2006
- Rufinamide.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2007
- Rufinamide add-on therapy for drug-resistant epilepsy.The Cochrane database of systematic reviews · 2020
- Rufinamide.2012
- Rufinamide.Drugs of today (Barcelona, Spain : 1998) · 2007
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 238.066617
- Has use
- medication
Show 6 more facts
- chemical formula
- C₁₀H₈F₂N₄O
- World Health Organisation international non-proprietary name
- rufinamide
- canonical SMILES
- C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F
- subject has role
- anticonvulsant agent
- defined daily dose
- 1.4
- Commons category
- Rufinamide
via Wikidata · CC0